Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Newsletters

Sen. Warren asks FTC to review CVS Health’s $10.6B acquisition of Oak Street Health

According to Warren, the FTC should scrutinize any healthcare deal that threatens competition, increases prices and reduces the quality of care.

Thumbnail

Feds may soon take action against Amazon’s monopoly status

Federal investigations that began in 2019 into Amazon’s potential abuse of power and consumer privacy violations may soon come to fruition with lawsuits to block the company's monopoly status, Politico reported. 

 

Thumbnail

Physician sentenced in $515M pain cream fraud scheme

Gregory Auzenne, MD, a pain management specialist from Meridian, Mississippi, has been sentenced in connection with a $515 million fraud scheme over pain cream.

Thumbnail

California partners with Civica Rx for affordable insulin

The state of California and Civica Rx have penned a 10-year deal to deliver insulin at a reduced rate. The medicines will be available in vials and prefilled pens under the CalRx label. 

Thumbnail

Healthcare disparities, uninsured rate both improving

In the last few years, uninsured rates dropped to a historic low of 8%, while racial disparities across healthcare have also vastly improved, according to a new report from the Commonwealth Fund.

Healthcare fraud running rampant in South Florida

South Florida is “ground zero” for healthcare fraud, with companies popping up left and right ready to bilk Medicare and Medicaid for millions of dollars.

Pfizer recalls 4 million units of migraine medicine

The recalled products are not child resistant, posing a poison risk if the contents are swallowed by young children.

Medicare money payment physician

These 27 drugs will be subject to Medicare rebates

The Medicare Prescription Drug Inflation Rebate Program will lower coinsurance for Medicare Part B beneficiaries for certain drugs, with savings between $2 and $390 per average dose starting April 1.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.